2025-05-28 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc (TGTX), incorporating the provided data.  I'll format it as a brief English report with key figures first, followed by analysis.

**Report on TG Therapeutics Inc (TGTX)**

**1. Performance Summary**

*   **Ticker:** TGTX
*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **Cumulative Return (TGTX):** 66.61%
*   **Cumulative Return (S&P 500/VOO):** 83.14%
*   **Return Disparity:** -16.5 (Relative Disparity: 19.4)
*   **Last Price:** $35.24

**2. Detailed Analysis**

**2.1. Relative Performance & Alpha/Beta Analysis**

The cumulative return of TGTX is 66.61%, underperforming the S&P 500 (VOO) which has a cumulative return of 83.14%. The current disparity is -16.5. The relative disparity of 19.4 suggests that TGTX's performance is near the lower end of its historical range compared to the S&P 500.

Here's the Alpha/Beta data in a table:

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -6.0%   | 56.5% | -35.0%  | -0.1   | 1.3    |
| 2016-2018  | -8.0%   | 58.6% | -26.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 58.6% | 44.0%   | -0.0   | 1.8    |
| 2018-2020  | 402.0%  | 58.6% | 377.0%  | -0.1   | 8.3    |
| 2019-2021  | 125.0%  | 63.5% | 70.0%   | -0.2   | 3.0    |
| 2020-2022  | -76.0%  | 70.4% | -82.0%  | -0.3   | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -367.0% | -0.8   | 2.7    |
| 2022-2024  | 71.0%   | 73.1% | 54.0%   | -1.0   | 4.8    |
| 2023-2025  | 73.0%   | 84.4% | 43.0%   | 0.3    | 5.6    |

*   **Analysis:** The table highlights periods of significant outperformance (e.g., 2018-2020) and underperformance (e.g., 2021-2023).  The negative Beta values suggest an inverse correlation with the market, which is unusual.  The Alpha values show periods where TGTX significantly exceeded or fell short of what would be expected based on its Beta.  The MDD (Maximum Drawdown) indicates substantial risk in holding TGTX.  The Cap(B) shows the market capitalization in billions.

**2.2. Recent Price Action**

*   **Price:** $35.24
*   **Previous Close:** $34.57
*   **Change:** 1.94%
*   **5-day Moving Average:** $34.74
*   **20-day Moving Average:** $36.57
*   **60-day Moving Average:** $38.06

*   **Analysis:** The current price is above the 5-day moving average but below the 20-day and 60-day moving averages, indicating a potential short-term upward trend but a possible longer-term downtrend. The recent price increase of 1.94% suggests some positive momentum.

**2.3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 52.21
*   **PPO:** -0.0714
*   **Hybrid Signal:** Cash_80%_Sell (80% of holdings)
*   **Delta_Previous_Relative_Divergence (20-day):** 0.2 (+) (Short-term increase)
*   **Expected Return:** -203.2%

*   **Analysis:** The MRI suggests a low-risk environment, but the Hybrid Signal recommends selling 80% of holdings and holding a high cash position.  The RSI is neutral.  The PPO is slightly negative, indicating a potential downtrend in momentum. The positive change in relative divergence suggests short-term upward momentum compared to the S&P 500.  However, the very negative expected return (-203.2%) suggests significant projected underperformance compared to the S&P 500 over the long term if dollar cost averaging. The significant price change from the previous close might indicate a news-driven event.

**2.4. Recent News & Events**

*   **Key Developments:** Recent news highlights major business developments, regulatory changes, or market events. Analysts are discussing the company's recent performance and outlook. The stock has shown notable volatility. Experts advise monitoring recent news and company announcements.

*   **Analysis:** The news indicates that TGTX is currently subject to significant market attention and potentially volatile price movements. Investors should pay close attention to specific news releases and analyst reports.

**2.5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2024-05-06 | -0.07 | 0.06 B$   |
| 2025-05-09 | -0.07 | 0.06 B$   |

*   **Analysis:** The recent earnings data shows improving EPS and revenue trends, with the latest quarter (2025-05-09) showing positive EPS and the highest revenue in the period.

**2.6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |
| 2024-03-31 | $0.06B    | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-03-31 | $0.24B    | 2.13%    |
| 2024-12-31 | $0.22B    | 10.49%   |
| 2024-09-30 | $0.19B    | 2.02%    |
| 2024-06-30 | $0.18B    | 3.87%    |
| 2024-03-31 | $0.16B    | -6.69%   |

*   **Analysis:** Revenue has been increasing steadily.  Profit margins are very high, indicating strong operational efficiency. Equity is also increasing. ROE has fluctuated, with a significant spike in Q4 2024.

**3. Overall Assessment**

TGTX is a company showing recent improvements in earnings and revenue. Its high profit margins and increasing equity are positive signs.  However, it has significantly underperformed the S&P 500 recently. The mixed signals from the MRI (low risk) and the Hybrid Signal (sell 80%) suggest caution.  The negative expected return indicates potential long-term underperformance. The recent news and volatility highlight the need for careful monitoring.

**Recommendation:** Given the negative expected return, underperformance relative to the S&P 500, and the "Sell" signal, caution is advised. Investors should closely monitor upcoming news and earnings releases before making investment decisions.  The positive earnings trends and financial data warrant further investigation, but the overall picture is currently not strongly bullish.
